Stockreport

Kymera upgraded, MoonLake downgraded: Wall Street's top analyst calls [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF Top 5 Upgrades: Wolfe Research upgraded Kymera Therapeutics (KYMR) to Outperform from Peer Perform with a $65 price target. The timing of STAT6 readout in 2025 is clo [Read more]